Sugi Predict

Sugi Predict / Compounds / SCHEMBL417405

SCHEMBL417405

SCHEMBL417405

N#Cc1cccc(-c2oc(C(=O)N3CCSC3)cc2-c2cc(F)cc(Cl)c2)c1

nearest known ligand 0.41

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ DPP4 P27487 5/20 0.41
▸ DPP7 Q9UHL4 3/20 0.41
▸ EIF4A3 P38919 3/20 0.37
▸ METAP2 P50579 1/20 0.36
▸ MCHR1 Q99705 4/20 0.34
▸ UTS2R Q9UKP6 1/20 0.34
▸ PDE4B Q07343 2/20 0.33
▸ PRKAA2 P54646 1/20 0.33
▸ PDE4D Q08499 1/20 0.33
▸ CSNK1E P49674 2/20 0.33
▸ SLC6A7 Q99884 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL417014 0.85 MCHR1 (0.36) EIF4A3METAP2MCHR1UTS2RPRKAA2
SCHEMBL417013 0.85 MCHR1 (0.36) EIF4A3METAP2MCHR1UTS2RPRKAA2
SCHEMBL415849 0.84 EIF4A3 (0.41) EIF4A3MCHR1UTS2R
SCHEMBL416571 0.84 DPP4 (0.38) DPP4DPP7
SCHEMBL419745 0.83 EIF4A3 (0.36) EIF4A3METAP2MCHR1UTS2RPRKAA2
SCHEMBL419357 0.83 METAP2 (0.36) EIF4A3METAP2UTS2RPDE4BCSNK1E
SCHEMBL415935 0.82 METAP2 (0.35) EIF4A3METAP2MCHR1UTS2RPRKAA2
SCHEMBL420175 0.81 PTGDR2 (0.40) METAP2
SCHEMBL421428 0.80 PRKDC (0.42) SLC6A7
SCHEMBL421343 0.77 PGR (0.39) EIF4A3PDE4BPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2376479-B1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AICURIS GMBH & CO KG (DE) 2016-03-02 — — EP disclosed
EP-2376479-B1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AICURIS GMBH & CO KG (DE) 2016-03-02 — — EP disclosed
US-8324268-B2 Substituted furancarboxamides, and use thereof AICURIS GMBH & CO. KG (DE) 2012-12-04 — — US disclosed
US-8324268-B2 Substituted furancarboxamides, and use thereof AICURIS GMBH & CO. KG (DE) 2012-12-04 — — US disclosed
US-8324268-B2 Substituted furancarboxamides, and use thereof AICURIS GMBH & CO. KG (DE) 2012-12-04 — — US disclosed
US-20120022059-A1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2012-01-26 — — US disclosed
US-20120022059-A1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2012-01-26 — — US disclosed
US-20120022059-A1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2012-01-26 — — US disclosed
WO-2010075957-A1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2010-07-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022059-A1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AADAC, DDC, TPMT DPP4 706/4885DPP7 1217/4885EIF4A3 2020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.